Dr Shadman on the Need for a Clinical Consensus in the Evolving Treatment Landscape of DLBCL

Mazyar Shadman, MD, MPH, Innovators Network Endowed Chair, associate professor, Clinical Research Division, Fred Hutchinson Cancer Center; associate professor, Medical Oncology Division, University of Washington School of Medicine, discusses the complexities of treatment selection in diffuse large B-cell lymphoma (DLBCL) as novel agents continue to reshape frontline therapy. With emerging data and multiple active regimens available, treatment decisions increasingly rely on expert consensus rather than direct head-to-head comparisons. These considerations were discussed at the Bridging The Gaps: Leukemia, Lymphoma, and Multiple Myeloma meeting in Miami, Florida.